Parients with sepsis are frequently encountered in emergency departments and hospital wards, but may be at differents stages of the disease process. In the UK, Intesive Care National Audit and Research Centre data collaected in 2005 estimated that 36800 patients per year die of sepsis, more than the annual mortality from breast cancer and bowel cancer combined ( Daniels, 2007).

International guidelines were published in 2004 and updated in 2008 ( Delliger et al, 2008 ) aiming to improve promotion of evidence-based practice. While components of the guide lines continue to be the subject of the guide-lines continue to be the subject of debate prompt impact on mortality and morbidity.

[Descargar Documento en pdf ]

Interest in measuring gene expression to aid the tailoring of treatment of patients with malignant disease is increasing,1 and breast cancer has been the subject of particularly extensive investigation.2e4 Formalin-fixed paraffin-embedded (FFPE) material is the most readily available tissue resource, from which H&E-stained sections allow for assessment of routine histopathological metrics, and immunohistochemistry (IHC) is routinely performed to assess for protein expression to guide clinical decision making.

Until recently, molecular analysis was hindered by the fact that RNA from FFPE tissue is extensively degraded. Formalin fixation cross-links nucleic acids and proteins, making the molecules rigid and susceptible to shearing, and extracted RNA is highly fragmented.5 However, technological developments have allowed gene expression profiling to be conducted on FFPE material, and quantitative real-time PCR (qRT-PCR)

[Descargar Documento en pdf ]

Approximately 90 women per 100,000 are diagnosed yearly with breast cancer in Israel [1]. Breast cancer remains among the most common cancers in women, and the most common cause of death among women between the ages of 40 and 79 [2]. Several large randomized clinical trials demonstrated the benefit of hormonal therapy in patients with estrogen receptor-positive (ER+) early-stage breast cancer (ESBC). An important decision for a patient with ER+, lymph node-negative (LN-) ESBC is whether to also undergo adjuvant chemotherapy after primary surgery to prevent or delay distant recurrence.

Chemotherapy-related adverse events occur in almost all patients, and more than 1 in 10 women experience a serious or life-threatening event [3]. Between 1 in 100 and 1 in 500 women die from side effects related to the administration of chemotherapy.

[Descargar Documento en pdf ]

All infants born during the period September 1, 2004, to February 28, 2006, with a birth weight of less than 1500 g were eligible for the original double-blind trial. The selection criteria for the study included the following: (1) radiographic evidence of severe respiratory distress syndrome (RDS) requiring mechanical ventilation within 4 hours after birth; (2) requirement of fractional inspired oxygen (FIO2) of $0.6; and (3) absence of severe congenital abnormalities and lethal cardiopulmonary disorders.

We believed that these infants were at high risk of developing CLD. Infants received either a mixture of budesonide and surfactant (treatment group) or surfactant only (control group). In the treatment group, infants were administered a mixture of 0.25 mg/kg budesonide (Pulmicort nebulizing suspension, Astra Zeneca, Lund, Sweden) and 100 mg/kg beractant (Servanta, Abbott, Columbus, Ohio). In the control group, infants were given 100 mg/kg beractant only.

[Descargar Documento en pdf ]

Rationale Antibiotic therapy for early Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) is effective, but the optimal therapeutic regimen and duration for early treatment remains unclear. The EarLy Inhaled Tobramycin for Eradication (ELITE) study was designed to assess the efficacy and safety of two regimens (28 and 56 days) of tobramycin inhalation solution (TIS) 300 mg/5 mL (TOBI®) twice daily for the treatment of early onset P.

aeruginosa infection in CF patients. Methods In this open-label, randomised, multicentre study, CF patients (aged =6 months) with early P. aeruginosa infection were treated for 28 days with TIS twice daily administered by the PARI LC PLUS™ jet nebuliser. After 28 days, patients were randomised 1:1 to either stop TIS (n=45) or to receive a further 28 days of TIS (n=43).

[Descargar Documento en pdf ].

All children received cyclosporine A (initial trough levels between 170 and 200 lg/L) and prednisolone (starting dose 15 mg/m2) as primary immunosuppression. Furthermore, all children received two doses of basiliximab (Simulect; Novartis Pharma GmbH, Basel, Switzerland) on days one and four post-transplant. The corticosteroids were continously tapered.

Clinically suspected acute graft rejection was confirmed by percutaneous liver biopsy and histologic grading according to the Banff criteria (8) and was treated with a three- to five-day course of intravenous methylprednisolone bolus therapy (10 mg/kg/day).

[Descargar Documento en pdf ].

Major postpartum hemorrhage (PPH) is a life-threatening complication of labor, which mostly occurs without any warning, predictive signs and symptoms, and often, in absence of predisposing conditions.1 Severe PPH, which is traditionally defined as blood loss of Z500mL after vaginal delivery and Z1000mL after a caesarean delivery in the first 24 hours postpartum, accounts for nearly one-quarter of all maternal deaths world-wide, with an estimation of 125,000 deaths per year.

Currently, the therapeutic strategies for the management of severe PPH are largely standardized. The cornerstone of massive PPH consists of the administration of uterotonic drugs, infusion of large quantities of colloids-crystalloids and blood components

[Descargar Documento en pdf ].

The annual incidence of septic shock in the adult Australian population is 0.77 per 1000, corresponding to 15700 new cases each year. frustratingly, despite significant investment of resources, mortality is still about 37%.

A topic that the role of glucocorticoid supplementation in reducing mortality in septic. The uncertainty in this area arises from the inability of current tests to clearly identify who is truly corticosteroid " deficent " at a cellular level, ana hence requires administration of supplemental glucocoticoids.

[Descargar Documento en pdf ].

Abstract
Background: Recently in a report of a single
center a methods has been described to apply
surfactant via thin endotracheal catheter to very low birth.

Introduction.
In very-low-birth-weight infants ( VLBW infants, infants with a birth weight below 1500g )
serious side effects of mechanical ventilation-like air leaks and brochopulmonary dysplasia ( BPG )

[Descargar Documento en pdf ].

Objective: Evidence regarding the efficacy and safety of human recombinant activated protein C in severe sepsis is limited, especially outside of clinical trials. We sought to compare the outcomes of patients with septic shock who received early treatment with activated protein C to those who did not. Design, Setting, and Patients: A retrospective cohort study at 404 U.S. hospitals. We studied 33,749 patients with sepsis who were admitted to intensive care and administered antibiotics and vasopressors within 2 days of admission.

Measurements and Main Results: Hospital mortality, intracranial and gastrointestinal hemorrhage, major transfusion. Compared to the entire cohort, the 1576 activated protein C-treated patients included in the matched analysis were younger (mean age, 61 vs. 67), more likely to be white (70% vs. 63%), and had fewer comorbidities.
[Descargar Documento en pdf ].

Factor VII deficiency is one of the 'rare inherited disorders of coagulation.' Few cases of Factor VII deficiency have been reported during pregnancy, a state which could potentially cause fatal haemorrhage. Here we report a case of a pregnant lady with a history of heavy menorrhagia and multiple first pregnancy failures. Delivery was carried out via Caesarean section due to non-reassuring foetal heart monitoring. Patient was treated with Fresh Frozen Plasma (FFPs) and Factor VII concentrates, however, the patient developed bleeding postoperatively.

Literature indicates that whilst Factor VII levels rise during pregnancy in normal women, no increase is seen in homozygous cases, whereas there is a moderate rise in heterozygous individuals. History of heavy menorrhagia, multiple first pregnancy failures and a positive family history for bleeding disorders necessitate investigation and monitoring of Factor VII levels during pregnancy
[Descargar Documento en pdf ].

The literature on the use of recombinant factor VIIa (rFVIIa), which was initially used in hemophiliac patients with inhibitors, for hemorrhages that cannot be managed with conventional methods or operations that cannot be performed safely is increasingly growing. This study presents a group of nonhemophiliac patients with hemorrhagic problems or hemorrhage risk for some interventions that were successfully resolved with the use of rFVIIa. The patient group was composed of 20 patients with different disorders resulting in similar results as hemorrhage or hemorrhage risk. Most of the patients were diagnosed with liver disorders primary or secondary to other diseases.

The remaining cases were patients with leukemia, sepsis, intracranial hemorrhage, and burn. Some of the patients had multiple problems like a patient with liver disorder and intracranial hemorrhage or a leukemia patient with sepsis and disseminated intravascular coagulation. rFVIIa had been administered to the patients at dosages between 70 and 150 µg/kg up to 6 doses with 2-hour to 3-hour intervals.
[Descargar Documento en pdf ].

In an analysis of clinical trials of antiinflammatory agents in patients with sepsis, Eichacker et al reported that treatment efficacy was dependent on the risk of death (2). These authors propose that the pathophysiological events found in the sickest patients closely reflect the pathology found in preclinical animal models of sepsis, in which placebo mortality rates approaching 100% are the norm. However, the assumption that there is a linear relationship between severity and potential to respond to therapy may be too simplistic.

Indeed, some interventions may have greater benefit in patients with moderate disease severity. [Descargar Documento en pdf ].

About 50% of the patients with septic shock do not survive. Intesivists have their disposal several antibiotics. Although sesistance is a critical issue, pa-resistant pathogens exceptionally remain reported in the literature.

The market size of sepsis is large because, in the US or the EU, severe sepsis affects 750,000 hospitalized patients. In the intensive care unit, 15% of patients. [Descargar Documento en pdf ].

Recombinant activated factor VII (rFVIIa) has been successfully used ‘‘off-label’’ in patients with refractory lifethreatening hemorrhage. Intravenous rFVIIa was given to 31 patients unresponsive to standard therapy with blood products and surgical reexploration, who were bleeding due to trauma, surgery, organ transplantation, liver cirrhosis, ruptured uterus. We recorded their coagulation and hematologic profiles, acid-base balance, blood loss, number of red blood cells (RBC).

The need for RBC, platelet, and plasma transfusion decreased significantly after rFVIIa, with a consequent significant improvement in clotting of test hematocrit, pH, and bicarbonates. Four patients had adverse events potentially related to rFVIIa. The survival rates after 1 and 30 days were 48.4% and 29.1%, respectively.
[Descargar Documento en pdf ].

Problematic bleedings is a common issue surgery for aortic dissection. Coagulopathy mat persistedespite approrite treatment with blood cells, plasma, factor concentrates and antifibrinolytics.

Hemostasis is a central problem in sugery for acuteaortic dissection. Bleeding in these patients is an important cause of morbidity and mortality. [Descargar Documento en pdf ].

Immunoglobulin mitigates autoimmune disease and facilitates acceptance of ABO-incompatible transplanted organs. To test the hypothesis that treatment with immunoglobulin is associated with improved graft survival and a decreased rate of allograft rejection, a cohort study of primary liver transplant recipients in the Studies of Pediatric Liver Transplantation registry was performed. The outcomes of 336 pediatric liver transplant recipients who received immunoglobulin within 7 days of liver transplantation were compared with the outcomes of 1612 recipients who did not receive immunoglobulin.

The outcome measures were patient survival, death-free graft survival, and allograft rejection. The Kaplan-Meier probability of patient survival was not different between patients treated with immunoglobulin and patients who did not receive immunoglobulin. Death-free graft survival was increased in patients treated with immunoglobulin (hazard ratio of death-free survival
0.57, P
0.014). The probability of allograft rejection at 3 months was 31% for patients treated with immunoglobulin versus 40% for patients who did not receive
immunoglobulin [Descargar Documento en pdf ].

Activated protein C (APC) is a natural anticoagulant that plays an important role in coagulation homeostasis by inactivating the procoagulation factor Va and VIIIa. In addition to its anticoagulation functions, APC also has cytoprotective effects such as anti-inflammatory, anti-apoptotic, and endothelial barrier protection. Recently, a recombinant form of human APC (rhAPC or drotrecogin alfa activated; known commercially as ‘Xigris’) was approved by the US Federal Drug Administration for treatment of severe sepsis associated with a high risk of mortality.

Sepsis, also known as systemic inflammatory response syndrome (SIRS) resulting from infection, is a serious medical condition in critical care patients. In sepsis, hyperactive and dysregulated inflammatory responses lead to secretion of pro- and antiinflammatory cytokines, activation and migration of leucocytes, activation of coagulation, inhibition of fibrinolysis, and increased apoptosis. Although initial hypotheses focused on antithrombotic and profibrinolytic functions of APC in sepsis, other agents with more potent anticoagulation functions were not effective in treating severe sepsis. [Descargar Documento en pdf ].

Despite the project increase in then tratment of sepsis in children in the future, there are specific opportunities to improve the management of the condition.

An estimated 25-42% of adult sepsis patients develop acute respiratory distress syndrome ( ARDS ), which requires mechanical ventilation ( MV ). [Descargar Documento en pdf ].

We undertook a multi-hospital collective study to evaluate outcomes of neonatal respiratory distress syndrome (RDS) patients treated with pulmonary surfactant (PS) over 17 yr in Korea (Group I; 1990/91, Group II; 1996, Group III; 2002, and Group IV; 2007). There were 60 neonates in Group I (16 hospitals), 1,179 in Group II (64), 1,595 in Group III (62), and 1,921 in Group IV (57).

We adopted Bomsel’s classification to evaluate initial chest radiographic findings, categorized RDS severities, and classified response types to PS therapy. Almost all cases were treated using a single dose in Groups I and II, but 19.5% received multiple-dose therapy in Group IV. In Group IV, Bomsel’s stages III and IV composed 62.9% and initial severities of mild, moderate, and severe RDS were 23.0%, 42.0%, and 35.0%. More infants showed good response in Groups II, III, and IV than in Group I (71.7%, 66.8%, and 69.2% vs. 58.3%). [Descargar Documento en pdf ].

The development of tumor biomarkers ready for clinical use is complex. We propose a refined system for biomarker study design, conduct, analysis, and evaluation that incorporates a hierarchal level of evidence scale for tumor marker studies, including those using archived specimens. Although fully prospective randomized clinical trials to evaluate the medical utility of a prognostic or predictive biomarker are the gold standard, such trials are costly, so we discuss more efficient indirect “prospective – retrospective” designs using archived specimens.

In particular, we propose new guidelines that stipulate that 1) adequate amounts of archived tissue must be available from enough patients from a prospective trial (which for predictive factors should generally be a randomized design) for analyses to have adequate statistical power and for the patients included in the evaluation to be clearly representative of the patients in the trial; 2) the test should be analytically and preanalytically validated for use with archived tissue; 3) the plan for biomarker evaluation should be completely specified in writing before the performance of biomarker assays on archived tissue and should be focused on evaluation of a single completely defined classifier; and 4) the results from archived specimens should be validated using specimens from one or more similar, but separate, studies. [Descargar Documento en pdf ].

Excessive bleeding after cardiac surgery can result in increasedmorbidity andmortality related to transfusion- and hypoperfusion-related injuries to critical organ systems. Our objective was to review mechanisms that result in bleeding after cardiac surgery as well as current and emerging interventions to reduce bleeding and transfusion.

We discovered that of pointof- care (POC) tests of hemostatic function can facilitate the optimal management of excessive bleeding and reduce transfusion by facilitating administration of specific pharmacologic or transfusion-based therapy and by allowing physicians to better differentiate between microvascular bleeding and surgical bleeding. [Descargar Documento en pdf ].

The ANZHR began receiving data in May 2005 but includes retrospective cases dating back to 2000, with the first use in obstetric hemorrhage reported in 2002. More than 90 hospitals from New Zealand and all States and Territories of Australia currently contribute data to the Registry. We estimate that this represents approximately 50% of hospitals in Australia and New Zealand using rFVIIa, but these hospitals represent in excess of 83% of rFVIIa doses administered in the region.

Submitting hospitals are required to commit to supplying complete datasets. This commitment, audited by the Department of Epidemiology and Preventive Medicine, limits bias and prevents the reporting of only positive experiences.

Participating institutions have obtained approval from local Ethics Committees to collect deidentified information without patient consent for inclusion in the ANZHR. This report includes all patients who received rFVIIa as part of treatment for PPH. [Descargar Documento en pdf ].